dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - dimethyl fumarate - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
suphrex 12,5 mg cietās kapsulas
lv system service, latvia - sunitinibs - kapsula, cietā - 12,5 mg
suphrex 50 mg cietās kapsulas
lv system service, latvia - sunitinibs - kapsula, cietā - 50 mg
ebglyss
almirall, s.a. - lebrikizumab - dermatīts, atopisks - citi dermatoloģiski preparāti - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 un 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
nicorette invisipatch 10 mg/16 h transdermāls plāksteris
mcneil ab, sweden - nikotīns - transdermālais plāksteris - 10 mg/16 h
nicorette invisipatch 25 mg/16 h transdermāls plāksteris
mcneil ab, sweden - nikotīns - transdermālais plāksteris - 25 mg/16 h
nicorette invisipatch 15 mg/16 h transdermāls plāksteris
mcneil ab, sweden - nikotīns - transdermālais plāksteris - 15 mg/16 h
nicotinell tts 14 mg/24 h transdermāls plāksteris
glaxosmithkline dungarvan ltd., ireland - nikotīns - transdermālais plāksteris - 14 mg/24 h
nicotinell tts 21 mg/24 h transdermāls plāksteris
glaxosmithkline dungarvan ltd., ireland - nikotīns - transdermālais plāksteris - 21 mg/24 h